ACE2 and infection: To measure the efficacy of COVID-HIGIV against the SARS-CoV-2 infection in terms of clinical morbidity, mice transduced with adenovirus expressing human ACE2 were infected with SARS-CoV-2 (strain WA-1) and then treated with COVID-HIGIV (400, 100, 25 and 6.25 mg/kg, i.p. route) 6 h post infection.